London CA - Search Results

1

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.

London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J. London CA, et al. PLoS One. 2011;6(11):e27018. doi: 10.1371/journal.pone.0027018. Epub 2011 Nov 3. PLoS One. 2011. PMID: 22073242 Free PMC article.

2

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. London CA, et al. Clin Cancer Res. 2003 Jul;9(7):2755-68. Clin Cancer Res. 2003. PMID: 12855656 Clinical Trial.

3

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C. Lin TY, et al. Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26. Exp Hematol. 2008. PMID: 18657349 Free PMC article.

4

Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA. Fossey SL, et al. Among authors: london ca. BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81. BMC Cancer. 2009. PMID: 19284568 Free PMC article.

5

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.

McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. McCleese JK, et al. Among authors: london ca. Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660. Int J Cancer. 2009. PMID: 19544563

6

A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.

Liao AT, McCleese J, Kamerling S, Christensen J, London CA. Liao AT, et al. Among authors: london ca. Vet Comp Oncol. 2007 Sep;5(3):177-96. doi: 10.1111/j.1476-5829.2007.00137.x. Vet Comp Oncol. 2007. PMID: 19754789

7

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. Lin TY, et al. Among authors: london ca. Blood. 2010 May 27;115(21):4217-25. doi: 10.1182/blood-2009-07-231985. Epub 2010 Mar 16. Blood. 2010. PMID: 20233974 Free PMC article.

8

Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.

McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA. McMahon MB, et al. Among authors: london ca. Am J Vet Res. 2010 Jul;71(7):799-808. doi: 10.2460/ajvr.71.7.799. Am J Vet Res. 2010. PMID: 20594083 Free article.

9

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA. Fossey SL, et al. Among authors: london ca. BMC Cancer. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112. BMC Cancer. 2011. PMID: 21443800 Free PMC article.

10

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Fossey SL, et al. Among authors: london ca. BMC Cancer. 2011 Apr 11;11:125. doi: 10.1186/1471-2407-11-125. BMC Cancer. 2011. PMID: 21481226 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters